Specifically, future studies could investigate the direct inhibition of XOD activity by HD and explore the effects of specific mutations in the binding sites of URAT1, GLUT9, and ABCG2 on HD’s binding affinity. The gene discussed is SLC22A12; the disease is Huntington disease.